Redmile Group’s Royalty Pharma RPRX Stock Holding History

Redmile Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200,000	Closed	-$9.71M	–	88
2020 Q2	$9.71M	Buy	+200,000	New	+$9.9M	0.18%	68

Other funds holding RPRX

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RWJF

Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Redmile Group's RPRX Position: Q3 2020 in Review

Redmile Group sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 200,000 shares — an estimated $9.71M sold.

Redmile Group first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $9.71M in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

Redmile Group reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
Redmile Group sold 200,000 Royalty Pharma shares in Q3 2020, an estimated $9.71M.
Redmile Group first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
Redmile Group's Royalty Pharma position peaked at $9.71M in Q2 2020.
134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Redmile Group's 13F filing for Q3 2020, filed 16 Nov 2020.